Quotient Limited (QTNT) Issues Quarterly Earnings Results, Meets Estimates
Quotient Limited (NASDAQ:QTNT) issued its quarterly earnings results on Monday. The company reported ($0.55) EPS for the quarter, meeting the consensus estimate of ($0.55), Bloomberg Earnings reports. Quotient Limited had a negative net margin of 382.71% and a negative return on equity of 1,303.22%.
Shares of Quotient Limited (NASDAQ QTNT) traded up 6.63% during trading on Monday, reaching $5.63. 313,809 shares of the company traded hands. The stock’s market capitalization is $80.94 million. The firm has a 50 day moving average of $6.73 and a 200 day moving average of $6.74. Quotient Limited has a 52 week low of $3.75 and a 52 week high of $8.64.
In other Quotient Limited news, insider D J. Paul E. Cowan sold 45,032 shares of Quotient Limited stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $6.57, for a total transaction of $295,860.24. Following the completion of the sale, the insider now directly owns 26,666 shares in the company, valued at $175,195.62. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider D J. Paul E. Cowan sold 9,420 shares of Quotient Limited stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $6.11, for a total transaction of $57,556.20. Following the sale, the insider now owns 26,666 shares of the company’s stock, valued at $162,929.26. The disclosure for this sale can be found here. Insiders have sold 165,612 shares of company stock worth $1,061,671 over the last ninety days. 29.00% of the stock is owned by insiders.
Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Quotient Limited from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 26th. ValuEngine upgraded shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Finally, BTIG Research reiterated a “buy” rating and set a $22.00 price target on shares of Quotient Limited in a report on Tuesday, April 18th.
Quotient Limited Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.